

Review **Point-of-Care Lung Ultrasound in the Intensive Care Unit—The Dark Side of Radiology: Where Do We Stand?**

Marco Di Serafino 1,* ,†, Giuseppina Dell'Aversano Orabona 1,†, Martina Caruso ¹ , Costanza Camillo ¹ , Daniela Viscardi ² , Francesca Iacobellis ¹ [,](https://orcid.org/0000-0003-4604-7384) Roberto Ronza ¹ , Vittorio Sabatino ¹ , Luigi Barbuto ¹ , Gaspare Oliva ¹ and Luigia Romano ¹

- ¹ Department of General and Emergency Radiology, "Antonio Cardarelli" Hospital, 80131 Naples, Italy; giuseppina.dellaversanoorabona@aocardarelli.it (G.D.O.); martina.caruso@aocardarelli.it (M.C.); costanza.camillo@aocardarelli.it (C.C.); francesca.iacobellis@aocardarelli.it (F.I.); roberto.ronza@aocardarelli.it (R.R.); vittorio.sabatino@aocardarelli.it (V.S.); luigi.barbuto@aocardarelli.it (L.B.); gaspare.oliva@aocardarelli.it (G.O.); luigia.romano@aocardarelli.it (L.R.)
	- ² Department of Intensive Care and Resuscitation, "Antonio Cardarelli" Hospital, 80131 Naples, Italy; daniela.viscardi@aocardarelli.it
- ***** Correspondence: marco.diserafino@aocardarelli.it
- These authors contributed equally to this work.

Abstract: Patients in intensive care units (ICUs) are critically ill and require constant monitoring of clinical conditions. Due to the severity of the underlying disease and the need to monitor devices, imaging plays a crucial role in critically ill patients' care. Given the clinical complexity of these patients, who typically need respiratory assistance as well as continuous monitoring of vital functions and equipment, computed tomography (CT) can be regarded as the diagnostic gold standard, although it is not a bedside diagnostic technique. Despite its limitations, portable chest X-ray (CXR) is still today an essential diagnostic tool used in the ICU. Being a widely accessible imaging technique, which can be performed at the patient's bedside and at a low healthcare cost, it provides additional diagnostic support to the patient's clinical management. In recent years, the use of point-of-care lung ultrasound (LUS) in ICUs for procedure guidance, diagnosis, and screening has proliferated, and it is usually performed at the patient's bedside. This review illustrates the role of point-of-care LUS in ICUs from a purely radiological point of view as an advanced method in ICU CXR reports to improve the interpretation and monitoring of lung CXR findings.

Keywords: intensive care unit; chest X-ray; lung ultrasound; point-of-care ultrasound

1. Introduction

The anterior–posterior supine chest X-ray (CXR) is a routine investigation performed in intensive care units (ICUs). Being a widely accessible imaging technique, which can be performed at the patient's bedside and at a low healthcare cost, it provides additional diagnostic support to the clinical examination of patients who usually require respiratory assistance and constant monitoring of vital functions and devices [\[1\]](#page-16-0). However, its limitations in terms of technical and diagnostic performance are equally well known when compared to both a standard CXR and the better performing and more panoramic chest computed tomography (CT) scan, with image quality often resulting in a frustrating experience for both the clinician, who has to manage a critical patient, and the radiologist, who has to provide the best diagnostics guidance [\[2\]](#page-16-1). The technical limitations of the image produced are mitigated by the widespread availability of sufficiently powered X-ray tubes, image digitization, and a rigorous execution technique. Nevertheless, interpretative shortcomings in the cardiopulmonary findings obtained remain, which are unavoidable and inherent in the method [\[1–](#page-16-0)[4\]](#page-16-2). If on the one hand the chest CT scan can be considered the diagnostic gold standard in view of the critical state of these patients, it is quite understandable that,

Citation: Di Serafino, M.; Dell'Aversano Orabona, G.; Caruso, M.; Camillo, C.; Viscardi, D.; Iacobellis, F.; Ronza, R.; Sabatino, V.; Barbuto, L.; Oliva, G.; et al. Point-of-Care Lung Ultrasound in the Intensive Care Unit—The Dark Side of Radiology: Where Do We Stand? *J. Pers. Med.* **2023**, *13*, 1541. [https://](https://doi.org/10.3390/jpm13111541) doi.org/10.3390/jpm13111541

Academic Editor: Ovidiu Alexandru Mederle

Received: 24 September 2023 Revised: 23 October 2023 Accepted: 24 October 2023 Published: 26 October 2023

Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license [\(https://](https://creativecommons.org/licenses/by/4.0/) [creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/) $4.0/$).

since they are critical patients, they cannot be easily transported to the diagnostic radiology departments in order to undergo a chest CT scan [\[5–](#page-16-3)[7\]](#page-16-4).

In addition, the frequency of diagnostic procedures required for these patients, often with daily monitoring of the chest, is to date still a widely controversial issue, and anterior–
suscitation team in GYP surfaces and at the position (abodition till the diagnosis and management) posterior supine CXR performed at the patient's bedside is still the best solution [\[8–](#page-16-5)[10\]](#page-16-6).

The well-established role of bedside lung ultrasound (LUS) performed by the resusci-
ment of the critical procedures to be interventional procedures to be interventional procedures to be interventional procedures to be int tation team itself represents a crucial turning point in the diagnosis and management of the critically ill patient as well as a guide to the interventional procedures to be performed at the patient of devices (Figure 1) $\frac{1}{2}$. the patient's bedside, such as pleural drainage or the insertion and monitoring of devices (Figure [1\)](#page-1-0) [\[11](#page-16-7)[–13\]](#page-17-0).

Figure 1. Utility of LUS in the ICU. Modified from [\[11\]](#page-16-7).

LUS is thus widely accepted in several codified clinical management protocols, as summarized in Table [1](#page-1-1) [\[5,](#page-16-3)[14,](#page-17-1)[15\]](#page-17-2).

Table 1. Validated clinical management LUS protocols.

Validated Clinical Management LUS Protocol	Purpose
BLUE protocol (Bedside Lung Ultrasonography in Emergency)	Emergency protocol for immediate diagnosis of acute respiratory failure.
FALLS protocol (Fluid Administration Limited by Lung Sonography)	Emergency protocol designed to sequentially rule out differential diagnoses such as cardiogenic and hypovolemic shock, allowing an early diagnosis of septic shock.
CAUSE protocol (Cardiac Arrest Ultrasound Exam)	Emergency protocol in cardiac arrest management. It has the potential to reduce the time required to determine the etiology of a cardiac arrest and thus decrease the time between arrest and appropriate therapy.

posterior supine CXR are encouraging enough to make it an attractive and often alternative Furthermore, the specificity and sensitivity of LUS when compared with anterior– ϵ ,5,16]. choice to CXR (Table [2\)](#page-2-0) $[4,5,16]$ $[4,5,16]$.

> Furthermore, the specific with anterior of LUS when compared with an extremely served with an extension partial view, limited to artifactual deductions of the subpleural lung parenchyma, which is highly subjective with the risks of operator dependence [4]. The integration of these methods, i.e., CXR and LUS, could be an incisive turning point, especially in complex All this is also amplified in view of the method's proximity to resuscitation areas, its high clinical value, and the absence of the use of ionizing radiation, albeit settling for a clinical settings such as ICUs, where management decisions must be made rapidly and coordinated among the various specialists [\[17](#page-17-4)[,18\]](#page-17-5).

> In this imaging review, we provide some food for thought by drawing on our organizational expertise in interpreting CXR findings and lowering the number of serial CXR checks

through the use of LUS as a clinical radiology point of care. This is conducted solely to supplement the CXR findings, monitor those that are readily accessible to the investigation itself, and reduce the produced radiant dose. Finally, but just as importantly, we focus more on the CXR reading through a more insightful echo-mediated clinical interpretation (Figure [2\)](#page-3-0).

Table 2. Lung ultrasound and chest X-ray sensitivity and specificity in many lung diseases. Modified from [\[5\]](#page-16-3).

Table [3](#page-2-1) shows the main pleural–parenchymal complications observed in ICUs that are the subject of this imaging review [\[19\]](#page-17-6).

Table 3. ICU pleural–parenchymal and device complications grouped by CXR general findings with literature references reporting LUS-validated findings.

They are divided into three specific paragraphs where the use of LUS, as a methodological advance in the bedside CXR reports in ICUs, is crucial for diagnosing and monitoring areas of decreased transparency around the chest found on X-rays (atelectasis, pneumonia, pleural effusion, pulmonary edema, acute respiratory distress syndrome (ARDS), and pulmonary contusions), in pneumothorax and device monitoring.

Figure 2. Two examples of CXR and LUS diagnostic integration. Bedside CXR (a,d) and LUS diagnostic integration (b,c,e). In the first case (top line) the CXR showed small, blurred opacities in the left inferior pulmonary field (**a**; star); LUS of the left basis confirmed the consolidative area with the left inferior pulmonary field (**a**, star); LUS of the left basis confirmed the consolidative area with hyperechogenic spots as signs of an air bronchogram (**b**; star). In the second case (below line), the hyperechogenic spots as signs of an air bronchogram (**b**, star). In the second case (below line), the second CXR showed small, blurred opacities in the inferior pulmonary field bilaterally (**d**, arrowhead); LUS confirmed areas of lung consolidation with an air bronchogram in the lower right and left pulmonary fields without pleural effusion (**c**,**e**, arrowhead).

$T_{\rm eff}$ shows the main pleural–parenchymal complications observed in ICUS that $T_{\rm eff}$ 2. Characterizing and Monitoring Areas of Decreased Transparency on the CXR

decreased transparency found on X-rays and also defining their solid or liquid nature and assisting drainage procedures (Figures 3 and 4) [28[–32\]](#page-17-14). LUS allows us to read the CXR by identifying and better characterizing areas of

ICU Pulmonary Acute Disease CXR General Findings LUS-Validated Findings pleural–parenchymal—but not necessarily subpleural—findings and cardio-mediastinal findings, just like an "open window to the chest". It is then supplemented by a targeted LUS investigation where these findings are available to the investigation itself, in order to make the diagnosis and undertake a correct evolutionary/resolutive monitoring in line make the diagnosis and undertake a correct evolutionary/resolutive monitoring in line
with the clinical course of the patient being treated [\[17,](#page-17-4)[18\]](#page-17-5). Furthermore, the potential role of contrast-enhanced ultrasound (CEUS) cannot be excluded [33-35]. CEUS could be a valuable diagnostic tool in differentiating peripheral areas of parenchymal-enhancing consolidation, such as pneumonic foci, atelectasis, or tumors from peripheral areas of noneffectively differentiate between benign and malignant peripheral pulmonary lesions due to an overlap of CEUS timings and patterns [\[36\]](#page-17-17). On the other hand, CEUS plays an additional role in diagnosing pleuritis or empyema and in guiding their drainage or the biopsy of However, the initial CXR is still an essential diagnostic tool to obtain an overview of enhancing parenchymal infarction [\[33–](#page-17-15)[35\]](#page-17-16). However, dynamic CEUS parameters cannot solid lesions [\[33](#page-17-15)[–35\]](#page-17-16). Figure [5](#page-5-0) illustrates an example of CEUS diagnostic utility for LUS.

Figure 3. A 30-year-old male patient admitted to the ICU for motor vehicle crash polytrauma resulting in multiple costal fractures and coma status. Bedside CXR (a) and LUS (b,c). (a) The CXR showed a blurred opacity in the left inferior pulmonary field (star); the basal field of the right lung appeared normally expanded (arrowhead). (c,d) LUS diagnostic integration performed on the same dependent and the basil collection in the basil region of the basil region of the basil region of the basil region of the presence of the pres day showed a fluid collection in the basal region of the right lung indicating the presence of a small pleural effusion (b, arrowhead) that was not clearly demonstrable in the bedside CXR and also an inhomogeneous hypo-echogenicity indicating a parenchymal consolidation in the basal region of the left lung without fluid collection (c, star).

Figure 4. A 27-year-old male patient admitted to the ICU for high-grade gunshot trauma with abdominal involvement and a clinically worsened condition after intubation. Bedside CXR (a,d) and LUS (b,c) . (a) The admission CXR showed a good expansion of the lungs with just a subtle and blurred opacity in the left inferior field (arrow). (b,c) LUS follow-up was performed after 2 days with evidence of hypoechogenic consolidative change in the left parenchyma (**b**, star) and a compact disposition of the B-lines as a sign of interstitial involvement (*c*, arrowhead) suggestive of phlogistic parenchymal complication. (**d**) The CXR confirmed the LUS findings showing some ovular opacity with a confluence trend occupying the left superior, middle, and inferior pulmonary fields (**d**, arrows).

Figure 5. A 70-year-old male patient admitted to the ICU with acute respiratory failure from **Figure 5.** A 70-year-old male patient admitted to the ICU with acute respiratory failure from chronic chronic obstructive pulmonary disease. Bedside CXR (**a**) LUS (**b**), CEUS (**c**), and CT scan (**d**). (**a**) The bedside CXR showed an area of pseudo-nodular consolidation (star) in the medium right obstructive pulmonary disease. Bedside CXR (**a**) LUS (**b**), CEUS (**c**), and CT scan (**d**). (**a**) The bedside CXR showed an area of pseudo-nodular consolidation (star) in the medium right pulmonary field. (**b**) LUS confirmed the parenchymal consolidation (star) that appears as a large heterogeneous hypoechoic area in the subpleural lung parenchyma. (**c**) CEUS examination with the administration of a sonographic contrast agent (Sonovue®, Bracco, Milan IT) showed no significative contrast enhancement in the pulmonary consolidation area (c, star) during the different phases of the study (c, arrowhead) concerning bronchial consolidation with the segmentary obstructive atelectatic area. (**d**) The CT scan highlighted areas of segmental parenchymal consolidation (**d**, star) caused by mucoid *2.1. Atelectasis* obstruction (**d**, arrow).

Ω telectasis refers to the collapse of alveoli resulting in a collapse of alveoli resulting in a concurrence of all Ω *2.1. Atelectasis*

The term atelectasis refers to the collapse of groups of alveoli resulting in a concurrent decrease in intrapulmonary airflow sustained by a dysfunction of the diaphragm, causing respiratory impairment, as in post-operative adhesions [\[37\]](#page-17-18). The main physiologic causes of atelectasis are compression of lung tissue, absorption of alveolar air, and impairment of surface [\[37–](#page-17-18)[39\]](#page-18-0).

Compression atelectasis occurs when the transmural pressure is reduced to a level that allows the alveolus to collapse. The supine position, positive-pressure ventilation, and muscle paralysis, when applied in ICUs, cause a cephalad shift of the diaphragm, which normally permits differential pressures in the abdomen and chest, resulting in a concurrent decrease in intrapulmonary airflow. In an anesthetized patient a cephalad diaphragm displacement, differential regional diaphragmatic changes, a shift of thoracic central vascular blood into the abdomen, and an increase in regional pleural pressure result in negative transpulmonary pressure and compressive atelectasis [\[37–](#page-17-18)[39\]](#page-18-0).

Resorption atelectasis or gas atelectasis stems from the resorption of gas from alveoli when communication between the alveoli and the trachea is obstructed. The obstruction leads to a non-ventilation of the distal airways; the gas residing in that region is completely absorbed by pulmonary blood flowing through that area. Aspirated foreign bodies, food and gastric contents, malpositioned endotracheal tubes, and mucous plugs favor the appearance of resorption atelectasis in ICUs [\[37–](#page-17-18)[39\]](#page-18-0). Resorption atelectasis can also be seen in acute bronchitis and pneumonia from the obstruction of small bronchi and bronchioles by inflammatory exudate and tumors (bronchogenic carcinoma, bronchial carcinoid, metastastates, lymphoma) [\[37–](#page-17-18)[39\]](#page-18-0).

A number of conditions impair muco-ciliary clearance: thoracic and abdominal pain, thoracic and abdominal surgery or trauma, central venous system depression, respiratory depressant medication, anticholinergic medication, general anesthesia, endotracheal intubation, ventilation with dry gases, inspiring oxygen in higher concentrations. Impairment of muco-ciliary transport causes the pooling of retained secretions in the smaller airways, and it favors the appearance of atelectasis. In the post-operative patient and in patients recovering in the ICU many factors are combined [\[40\]](#page-18-1).

Development of atelectasis is associated with the development of several pathophysiologic effects, including decreased compliance, impairment of oxygenation, increased pulmonary vascular resistance, and development of lung injury. Atelectasis produces alveolar hypoxia and pulmonary vasoconstriction to prevent ventilation–perfusion mismatching and to minimize arterial hypoxia [\[37–](#page-17-18)[40\]](#page-18-1). Atelectasis itself is often asymptomatic unless hypoxemia or pneumonia develops. Symptoms of hypoxemia tend to be related to acuity and extent of atelectasis. Dyspnea or even respiratory failure can develop with rapid, extensive atelectasis [\[37–](#page-17-18)[40\]](#page-18-1).

The main CXR sign is a lobar or sub-lobar parenchymal thickening often evident at the lower lobes with partial or total disappearance of the profile of the hemidiaphragms or cardiac silhouette and also with the mediastinum that is shifted toward the collapsed lung area [\[41,](#page-18-2)[42\]](#page-18-3).

On LUS, the common finding is the sign of tissue, the so-called pulmonary "hepatization", suggesting collapsed parenchyma with air bronchograms frequently static or unaffected by respiratory dynamics as they are trapped in the area of consolidation; the bronchi are often in a parallel arrangement, unlike the typical tree-like arrangement of the pneumonia consolidation, in line with a reduction in lung volume [\[5,](#page-16-3)[21,](#page-17-19)[29,](#page-17-20)[30,](#page-17-21)[38,](#page-17-22)[43\]](#page-18-4). Furthermore, in the collapsed parenchymal area the "lung sliding" is usually absent while the "lung pulse" appears more represented, which is a sign of the perception of the impact of cardiac activity on the collapsed lung [\[44\]](#page-18-5).

Figure [6](#page-6-0) is an example of CXR and LUS diagnostic integration in detecting atelectasis.

Figure 6. A 48-year-old male patient admitted to the ICU for post-traumatic subarachnoid hemorrhage and acute respiratory failure. Bedside CXR (a) and LUS (b). (a) The CXR showed an inhomogeneous opacity in the right inferior pulmonary field (arrowhead). (**b**) LUS confirmed a parenchymal consolidation area at the basis of the right lung (**b**, arrowhead) showing some hyperegeneric spinal conservation area at the basis of the hypothesis of a static brief of an angle of an angle of a chogenic spots as signs of a static bronchogram (**b**, arrows) related to the diagnostic hypothesis of an atelectatic area.

2.2. Pneumonia 2.2. Pneumonia

Pneumonia ranks among the more common nosocomial infections [45–47]. The Pneumonia ranks among the more common nosocomial infections [\[45](#page-18-6)[–47\]](#page-18-7). The mechanisms of contamination may depend on the aspiration of active flora in the oropharynx, inhalation of aerosols containing pathogenic microorganisms, or more rarely, hematogenous spread to the lungs $[45-47]$ $[45-47]$.

In ICUs, hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia In ICUs, hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) occur more frequently. HAP is a new pneumonia (a lower respiratory tract infection verified by the presence of a new pulmonary infiltrate on imaging) that develops more than

48 h after admission in non-intubated patients. VAP, the most common and fatal nosocomial infection in critical care, is a new pneumonia that develops after 48 h of endotracheal intubation. Importantly, by the time of VAP onset, patients may have already been extubated [\[45](#page-18-6)[–47\]](#page-18-7). Aspiration is an important contributor to the pathogenesis of HAP and VAP. Further, proton-pump inhibitors and histamine-2 receptor blockers, by suppressing acid production, can allow nosocomial pathogens to colonize the oropharynx and endotracheal tube and be aspirated [\[45](#page-18-6)[–47\]](#page-18-7). Owing to their low sensitivity and specificity, history and physical examination are considered suboptimal to confirm or exclude the diagnosis.

Guidelines recommend that a new pulmonary infiltrate at the CXR should be present to classify a hospitalized patient as having the diagnosis of pneumonia. Oxygen saturation (SpO2) and arterial gas analysis can provide important information about severity. In an attempt to determine whether a typical pathogen is the etiology of pneumonia, all patients should have a sputum specimen for Gram stain and culture as well as two sets of blood cultures obtained before the institution of antimicrobial therapy. Fluid samples from the pleural space and bronchoscopy represent invasive tests that are also useful in pneumonia diagnosis [\[45](#page-18-6)[–47\]](#page-18-7).

The CXR shows the presence and extent of the condition, any concurrent cavities, and the appearance of parapneumonic effusions or abscesses [\[41,](#page-18-2)[42\]](#page-18-3).

On LUS examination, areas of subpleural consolidation with a hypoechogenic echostructure, irregular margins, and of various shapes and sizes with a tendency to confluence can be found, often associated with the detection of dynamic air bronchograms or hyperechogenic punctiform foci representing air in the bronchi that moves in line with the respiratory excursion. Furthermore, if a significant peripheral abscess cavitation develops, it appears on the LUS as a colliquated central lacuna with debris and gas or with a pseudo-solid appearance related to suppuration development [\[5](#page-16-3)[,21,](#page-17-19)[29,](#page-17-20)[30,](#page-17-21)[43\]](#page-18-4).

Figure [4,](#page-4-1) Figure [7,](#page-8-0) and Figure [8](#page-8-1) show some examples of CXR and LUS diagnostic integration in detecting pneumonia.

2.3. Pleural Effusion

A pleural effusion is defined as an excess of pleural fluid within the pleural space. It represents a disturbance of equilibrium between production and resorption. Normally, a small amount of pleural liquid (5–10 mL, 0.1 mL/kg per hemithorax in healthy adults) exists within the pleural space [\[48\]](#page-18-8). The volume of the pleural fluid is determined by the balance of the hydrostatic and oncotic pressure differences that are present between the systemic and pulmonary circulation and the pleural space. Both the visceral and the parietal pleura play an important role in fluid homeostasis in the pleural space; especially, the parietal side of the pleura accounts for most of the production of pleural fluid and for most of its resorption [\[48](#page-18-8)[–50\]](#page-18-9). Excess fluid accumulation in the pleural space can be caused by both benign and life-threatening conditions. A transudate occurs when systemic factors influencing the formation and absorption of pleural fluid (hydrostatic and oncotic pressures) are altered so that fluid accumulates. The reason to make this differentiation is that the existence of a transudative pleural effusion indicates that systemic factors such as heart failure or cirrhosis are responsible for the effusion, with the existence of examples such as congestive heart failure, cirrhosis, nephrotic syndrome, urinothorax, hypoalbuminemia, and cerebrospinal fluid leak [\[48–](#page-18-8)[50\]](#page-18-9).

An exudative effusion indicates that local factors are responsible for the effusion. Malignant disease (carcinoma of any origin, but especially lung and breast; lymphoma; mesothelioma); infections (parapneumonic effusion; tuberculous pleurisy; fungal, parasitic or viral infections); autoimmune inflammatory diseases (systemic lupus erythematosus and other connective tissue diseases; rheumatoid arthritis); pulmonary embolism; intra-abdominal processes (pancreatitis; subphrenic/hepatic abscess); drugs (amiodarone, methotrexate, nitrofurantoin and others); traumatic hemothorax; cardiac bypass surgery; post-cardiac injury syndrome; and post-radiation therapy could cause exudative effusion [\[48–](#page-18-8)[50\]](#page-18-9).

Figure 7. A 36-year-old female patient admitted to the ICU for a comatose state related to cerebral hemorrhage with fever and dyspnea after endotracheal intubation. Bedside CXR (a) and LUS (b,c). (a) The CXR showed faint areas of decreased parenchymal transparency in the right and left inferior pulmonary field (a, arrowheads); (b). LUS confirmed the consolidative areas at the lung basis $\frac{1}{\sqrt{2}}$ (b,c, arrowheads) with hyperechogenic spots as signs of an air bronchogram (b,c, arrows) that moved in line with the respiratory excursion. The clinical scenario and imaging findings were suggestive of phlogistic bronchopneumonia.

admission into the ICU showed normal lung expansion with no evidence of parenchymal change. Figure 8. A 26-year-old male patient admitted to the ICU for a comatose state related to high-energy trauma due to a car accident. Bedside CXR (a,c) and LUS (b). (a) The CXR on the day of admission into the ICU showed normal lung expansion with no evidence of parenchymal change. (b) LSU was performed after 24 h endotracheal intubation with the onset of a respiratory worsening and showed an inhomogeneous area of mixed hypoechogenic change at the basis of the left lung (b, arrowhead) with some hyperechogenic spots suggestive of consolidation with an air bronchogram (b, arrow). (c) The CXR confirmed the LUS findings showing an area of reduced diaphony in the basal left field that was considered the manifestation of parenchymal consolidation (**c**, arrowhead). The clinical scenario and imaging findings were suggestive of phlogistic bronchopneumonia.

> Clinical assessment to determine the appropriate investigation and management is essential. Although symptoms specific to the underlying cause may be present, pleural effusions usually present with nonspecific symptoms such as dyspnea, cough, and pleuritic pain. Such symptoms, if present, reflect an inflammatory response of the pleura, a restriction of pulmonary mechanics, or a disturbance of gas exchange; the severity of these symptoms

depends on effusion size and the patient's cardiopulmonary reserve [\[48–](#page-18-8)[50\]](#page-18-9). The most common symptom of pleural effusion is dyspnea. The severity of dyspnea is only loosely correlated with the size of the effusion, and it could require patient endotracheal intubation and hospitalization in the ICU.

Detection of a pleural effusion by examination is determined by its size. A pleural effusion of less than 300 mL is likely to be clinically undetectable, whereas a large effusion (>1500 mL) may cause significant hemithorax asymmetry. Chest examination typically reveals dullness to percussion, the absence of fremitus, and diminished breath sounds or their absence. Distended neck veins, an S3 gallop, or peripheral edema suggests congestive heart failure, and a right ventricular heave or thrombophlebitis suggests pulmonary embolus [\[48–](#page-18-8)[50\]](#page-18-9).

Moderate effusion often goes undetected by CXR, especially by supine CXR, which can document abnormalities when the amount of pleural effusion reaches 175–525 mL; therefore, only when the amount of fluid increases, the hemithorax becomes hazy, the pulmonary vessels become less recognizable, and the profile of the hemidiaphragm fades and becomes unrecognizable [\[28,](#page-17-13)[41](#page-18-2)[,42\]](#page-18-3).

According to this evidence, the LUS plays an important role in the identification and quantification of small pleural effusions not detectable by CXR. Simple transudate fluid collections are evident on LUS as anechogenic spaces between the pleural layers; debris that moves on respiratory movement may also be present. A more compact septated collection with a tendency to sacculate may indicate a pleural empyema [\[5,](#page-16-3)[26](#page-17-11)[,29](#page-17-20)[,30\]](#page-17-21).

LUS may also be a guiding imaging tool both for diagnostic pleural drainage, rather LUS may also be a guiding imaging tool both for diagnostic pleural drainage, rather than for therapeutic pleural drainage or thoracentesis, and for follow-up procedures such than for therapeutic pleural drainage or thoracentesis, and for follow-up procedures such as iatrogenic pneumothorax occurrences [\[26](#page-17-11)[,50\]](#page-18-9). as iatrogenic pneumothorax occurrences [26,50].

Figures $\frac{1}{9}$ $\frac{1}{9}$ $\frac{1}{9}$ and [10](#page-10-0) show examples of CXR and LUS diagnostic integration in detecting pleural effusion. pleural effusion.

ALETTO

(D)

Figure 10. A 54-year-old male patient in respiratory failure. CT scan (a), CXR (b), and LUS (c). (a) The axial CT scan of the chest showed a parenchymal consolidation area with the air-fluid level in the the basal segments of the right inferior pulmonary lobe suggestive of a pleural empyema (**a**; arrow). basal segments of the right inferior pulmonary lobe suggestive of a pleural empyema (**a**, arrow). (**b**) The subsequent CXR control revealed a basal right-side decreased parenchymal transparency (**b**) The subsequent CXR control revealed a basal right-side decreased parenchymal transparency consistent with a persistent amount of the empyematous effusion (**b**; arrow). (**c**) LUS follow-up consistent with a persistent amount of the empyematous effusion (**b**, arrow). (**c**) LUS follow-up showed a better quantification of the residual fluid amount, with an inhomogeneous content of showed a better quantification of the residual fluid amount, with an inhomogeneous content of echogenic substance in suspension (**c**; arrow) and also confirmed the correct position of the surgical echogenic substance in suspension (**c**, arrow) and also confirmed the correct position of the surgical drainage tube (**c**; arrowhead). drainage tube (**c**, arrowhead).

2.4. Cardiogenic Pulmonary Edema

2.4. Cardiogenic Pulmonary Edema Pulmonary edema is defined as increased fluid in the interstitial and/or alveolar spaces of the lung parenchyma. Acute cardiogenic and/or volume overload edema usually have increased pulmonary venous pressure because of elevations in left atrial and left ventricle end-diastolic pressure [\[51](#page-18-10)[,52\]](#page-18-11).

wentricle end-diastolic pressure [51,52].

left ventricle end-diastolic pressure [51,52]. heart failure has many causes, including hypertension, myocarditis, acute onset cardiomyneart failure files hearty causes, merutaing trypertension, information, acade enser cardiality, opathy, left ventricle dysfunction or failure, papillary muscle dysfunction, ventricular septal rupture, acute severe aortic insufficiency, acute severe mitral regurgitation, arrhythmias, my-The most frequent cause of congestive heart failure is myocardial infarction, although ocardial contusion/post-cardiac arrest stunning, cardiac tamponade, toxic and metabolic, beta block or calcium channel antagonist overdose, and pheochromocytoma [\[51](#page-18-10)[,52\]](#page-18-11).

> Clinical presentation is characterized by shortness of breath at rest and worsens with exertion, tachypnea, tachycardia, and relative hypoxemia. The lung exam reveals crackles or gasps. Jugular venous pressure may be normal or increased. The S3 gallop on the electrocardiographic exam is relatively specific for cardiogenic edema. A focused exam for cardiac murmurs consistent with valvular stenosis, regurgitation, or signs of right heart failure is of high importance [\[51](#page-18-10)[,52\]](#page-18-11).

> On the CXR, when the edema is still confined to the interstitium, it occurs as a thickening of the associated spaces, especially in the declivities of the lungs where the hydrostatic pressure is higher, so that a thickening of the interlobular septa or so-called Kerley lines, thickening of the walls of the bronchi, shading of the vessel profile, and thickening of the subpleural interstitium can be detected $[41,42]$ $[41,42]$. As the edema worsens, vascular and bilateral cotton wool opacities with no aero-bronchogram appear [\[41,](#page-18-2)[42\]](#page-18-3). Usually, the heart is enlarged and pleural effusion coexists [\[41](#page-18-2)[,42\]](#page-18-3).

> Multiple B-lines tending to confluence (so-called white lung) are evident on LUS depending on the severity of the condition and are associated with pleural effusion, inferior vena cava ectasia, and heart failure [\[5](#page-16-3)[,14](#page-17-1)[,15,](#page-17-2)[29,](#page-17-20)[30\]](#page-17-21).

> Figure [11](#page-11-0) shows an example of CXR and LUS diagnostic integration in detecting cardiogenic pulmonary edema.

Figure 11. A 79-year-old male patient suspected of having pulmonary edema. CXR (a) and LUS (b,c). (a) On the CXR opacity of the middle and inferior field was detected bilaterally (a, arrowheads) with $\frac{1}{\sqrt{2}}$ with lung basis consolidation (**a**) arrow). (**b**,c) LUS integration showed on the right lung basis (**b**) α right lung basis consolidation (**a**, arrow). (**b**,**c**) LUS integration showed on the right lung basis (**b**) a pleural anechoic effusion (**b**, arrow) associated with a consolidative area (**b**, star); the evaluation of the right and left lungs (**c**) showed a compact appearance of the B-lines on the explorable lung areas in the intercostal space (**c**, arrowheads). In this case LUS allowed us to better clarify the nature of the CXR lung opacities.

2.5. Acute Respiratory Distress Syndrome 2.5. Acute Respiratory Distress Syndrome

ARDS is a syndrome of acute respiratory failure caused by non-cardiogenic pulmonary monary edema representing the most severe stage of acute lung damage due to alveolar– edema representing the most severe stage of acute lung damage due to alveolar–capillary endothelial damage with leakage of fluid from the intravascular to the extravascular endothelial damage with leakage of fluid from the intravascular to the extravascular vascular compartment [53]. ARDS accounts for 10% of ICU admissions, representing compartment [\[53\]](#page-18-12). ARDS accounts for 10% of ICU admissions, representing more than more than 3 million patients with ARDS annually [53,54]. ARDS progresses through 3 million patients with ARDS annually [\[53](#page-18-12)[,54\]](#page-18-13). ARDS progresses through several phases several phases (exudative, proliferative, and fibrotic) after a direct pulmonary or indirect (exudative, proliferative, and fibrotic) after a direct pulmonary or indirect extrapulmonary insult, and it is classified as low, moderate, and severe according to Berlin criteria [\[53,](#page-18-12)[54\]](#page-18-13).

ARDS initially manifests as dyspnea, tachypnea, and hypoxemia, then quickly evolves into respiratory failure. Identification of a specific cause for ARDS remains a crucial therapeutic goal to improve outcomes associated with ARDS. There is still no effective pharmacotherapy for this syndrome, and the treatment remains primarily supportive and includes mechanical ventilation, fluid management strategy, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury [\[53,](#page-18-12)[54\]](#page-18-13).

The CXR shows the presence of more or less homogeneously distributed patches at an already advanced stage in both lungs with less gravitational tendency and less confluence as well as evidence of an internal air bronchogram [\[41](#page-18-2)[,42\]](#page-18-3). It may regress, evolve into fibrosis, or in adverse cases show a mosaic evolution with temporal changes in opacities [\[41,](#page-18-2)[42\]](#page-18-3).

On a LUS, multiple B-lines with irregular distribution alternate with areas of hypoechogenic subpleural consolidation with concurrent air bronchograms [\[29,](#page-17-20)[30\]](#page-17-21). The pleural line is also frequently irregular [\[29](#page-17-20)[–31\]](#page-17-23). Furthermore, the possibility of highlighting healthy lung areas allows for orientation in the differential diagnosis of hydrostatic pulmonary edema [\[29–](#page-17-20)[31\]](#page-17-23).

Figure [12](#page-12-0) shows an example of CXR and LUS diagnostic integration in detecting and monitoring ARDS.

Figure 12. A 57-year-old female patient with acute respiratory failure during interstitial pneumonia **Figure 12.** A 57-year-old female patient with acute respiratory failure during interstitial pneumonia not related to SARS-CoV2 infection. Bedside CXR (a,c) and LUS (b). (a) The CXR revealed on the right side multiple small opacities with signs of interstitial thickening suggestive of an interstitial right side multiple small opacities with signs of interstitial thickening suggestive of an interstitial and alveolar infective process (a, arrow). (b) The LUS examination performed after 5 days showed in the middle right pulmonary field and on the left side a compact appearance of B-lines (**b**, arrowheads) associated with some areas of parenchymal consolidation (**b**, star) with an irregular pleural line (**b**, arrow) that was suggestive of ARDS complication, according to the clinical worsening refractory to therapies. (**c**) The CXR confirmed massive involvement of the interstitial compartment and bilateral consolidation of the parenchyma with an internal air bronchogram suggestive of ARDS according to the clinical scenario (**c**, arrowheads).

2.6. Pulmonary Contusion 2.6. Pulmonary Contusion

A pulmonary contusion is an entity defined as an alveolar hemorrhage caused by an A pulmonary contusion is an entity defined as an alveolar hemorrhage caused by an injury to the alveolar capillaries and pulmonary parenchymal destruction after blunt trauma. It is a common finding after mechanisms of injury that impart substantial kinetic energy to the thorax, and often the rate of pulmonary contusion is linearly associated with the severity of injury to the bony thorax. Lung tissue injury occurs when the chest wall bends inward following the trauma [\[22](#page-17-7)[,55\]](#page-18-14). The possible mechanisms are based on inertial effects, mainly on different tissue densities, light alveolar tissue, and heavy hilar structures. Rib fractures and their degree of displacement, as well as flail chest and penetrating mechanisms, contribute to the severity of the underlying lung injury [\[22](#page-17-7)[,55\]](#page-18-14). injury to the alveolar capillaries and pulmonary parenchymal destruction after blunt chest

Parenchymal lung injury leads to pathophysiologic changes, the severity of which depends on the extent of injury. The number of affected lobes has been reported to determine the outcome. The physiologic consequences of alveolar hemorrhage and pulmonary parenchymal destruction typically manifest themselves within 24–48 h of injury and usually resolve within approximately 7–14 days, but delayed deterioration may occur [\[22,](#page-17-7)[55\]](#page-18-14).

Clinical manifestations include increased work at breathing, respiratory distress with hypoxemia and hypercarbia. Patients may present with a rapid respiratory rate, rhonchi or wheezes, or even hemoptysis. Bleeding into uninvolved lung segments may cause bronchospasm and may compromise alveolar function [\[22,](#page-17-7)[55\]](#page-18-14).

On the CXR, pulmonary contusions appear as diffuse or patchy parenchymal opacities. However, CXRs have a low sensitivity in detecting foci of contusion, in view of the possible coexistence of hemothorax or pneumothorax [\[41](#page-18-2)[,42\]](#page-18-3).

In view of the fact that the areas of contusion are predominantly subpleural in extension and at the site of impact, LUS may document and monitor obvious foci of contusion as hypoechogenic areas with poorly defined margins often coexisting with multiple confluent B-lines [\[22,](#page-17-7)[29,](#page-17-20)[30\]](#page-17-21).

Figure [13](#page-13-0) shows an example of CXR and LUS diagnostic integration in detecting pulmonary contusion.

pulmonary contusion.

Figure 13. A 33-year-old male patient referred to the ICU after major trauma by defenestration. **Figure 13.** A 33-year-old male patient referred to the ICU after major trauma by defenestration. Bedside CXR (a) and LUS (b,c) . (a) The CXR revealed on the right side the presence of two thoracic tube drainages (**a**; arrows) after pneumothorax (not shown) with middle and lower right lung tube drainages (**a**, arrows) after pneumothorax (not shown) with middle and lower right lung zones indicating several confluent opacities (a, arrowheads). (b,c) LUS revealed on the same side the presence of a thick pleural line (\mathbf{b} , \mathbf{c} , arrow) with multiple B-line artifacts (\mathbf{b} , arrowheads) and hypoechoic alveolar consolidation (**c**; star) corresponding to lung contusion. hypoechoic alveolar consolidation (**c**, star) corresponding to lung contusion.

3. Confirming or Excluding Pneumothorax and Monitoring its Evolution

Pneumothorax is defined as the presence of air in the pleural space. It indicates the loss of visceral or parietal pleural membrane integrity, thereby allowing air from the loss of visceral or loss of visceral or parietal pleural membrane integrity, thereby allowing air from the en-pressures are negative throughout most of the respiratory cycle, air does not enter into the n
pleural space [\[27](#page-17-12)[,56\]](#page-18-15). Iatrogenic pneumothorax is one of the main iatrogenic complications in ICU patients, and its occurrence increases the duration of ICU and hospital stays. environment or respiratory tract to accumulate in the pleural space. Although intrapleural

Iatrogenic pneumothorax occurs chiefly as a complication of barotrauma related to me-chanical ventifiation of as a post-procedural event (transmoracic needie biopsy, subclaviant
vein catheterization, thoracentesis, transbronchial, lung biopsy, pleural biopsy) [\[27,](#page-17-12)[56\]](#page-18-15). The stays. development of lung-protective strategies for ventilation and of new material, techniques, chanical ventilation or as a post-procedural event (transthoracic needle biopsy, subclavian and recommendations for inserting central vein catheters (CVCs) makes iatrogenic pneumothorax largely preventable in routine practice. Nevertheless, its occurrence is closely related to the underlying disease, such as in patients with adult ARDS [\[27,](#page-17-12)[56\]](#page-18-15). Other causes of pneumothorax such as spontaneous or traumatic-acquired may represent an additional portion of patients admitted to the ICU who need diagnosis and monitoring [\[27](#page-17-12)[,56\]](#page-18-15).

Symptoms of a pneumothorax can include chest pain, shortness of breath, cough, and increases in heart rate or breathing.

Different treatments are used depending on the size of the air volume in the pleural space and the amount of pressure it puts on the lung [\[27](#page-17-12)[,56\]](#page-18-15). Small and asymptomatic iatrogenic pneumothoraxes often do not need any treatment and resolve spontaneously. Parenchymal lung damage can effectively heal, and the intrapleural air will be resorbed over time. In larger or symptomatic pneumothoraxes, simple manual aspiration or placement of a small catheter or chest tube attached to a Heimlich valve usually is successful. Tension pneumothorax presents as a life-threatening emergency that requires prompt recognition and treatment. When tension pneumothorax develops, urgent thoracic decompression is

(D)

recommended [27,56]. For this reason, it is understandable how an early diagnosis can lead to the best therapeutic direction.

On the CXR, radiolucent air and the absence of juxtaposed lung markings between a

and the risk of incurring and the risk of incurring and the risk of the risk of the risk of the risk of the r compressed lobe or lung and the parietal pleura are indicative of pneumothorax. Tracheal deviation and mediastinal shift occur in a large tensive pneumothorax [\[41](#page-18-2)[,42\]](#page-18-3). However, for the aforementioned diagnostic CXR limitations that are also due to the supine patient's position, the risk of incurring an occult small pneumothorax is not negligible where the failure to recognize it is important, especially if the patient must undergo ventilation $[27,56]$ $[27,56]$. In such contexts, LUS offers an important contribution to the diagnosis and in the same
way to monitoring way to monitoring.

On LUS, the most specific finding is the lung point, i.e., the boundary between the airy lung and pneumothorax visible as a change in physiological pleural sliding; the presence of air will also generate overlapping A-lines and the complete absence of B-lines [\[27](#page-17-12)[,29](#page-17-20)[,30\]](#page-17-21).

> Figure [14](#page-14-0) shows an example of CXR and LUS diagnostic integration in detecting pneumothorax.

FACTORY LA332

LUS (b). (a) The CXR showed the surgical drainage tube (arrowhead), with poor confidence on the entity of the residual pneumothorax. (**b**) LUS showed the presence of "lungs points" (arrow) confirming the residual pneumothorax that was not clearly demonstrable on the CXR.

4. Checking and Monitoring the Devices

A LETTO

Medical devices, including ventilators, infusion pumps, breathing and feeding support, and others, improve patient care and outcomes in the ICU. Despite the staff's ability to manage them, using them properly and checking their correct position reduces the development of adverse events associated with them [\[57\]](#page-18-16). The correct positioning of the various life-sustaining devices in the ICU represents a further diagnostic challenge in the correct reading of the CXR (Figure [15\)](#page-15-0) [\[41\]](#page-18-2).

Figure 15. Comparison between plain chest radiography and LUS in three different critical patients **Figure 15.** Comparison between plain chest radiography and LUS in three different critical patients in the intensive care unit. (a,b) CXR and LUS surgical drainage tube evaluation (the same patient as in Figure [10\)](#page-10-0) (a,b, arrow). (c,d) CXR and LUS nasogastric tube evaluation (c,d, star). (e,f) CXR and LUS endotracheal tube evaluation (**e**,**f**; arrowhead)*.* LUS endotracheal tube evaluation (**e**,**f**, arrowhead).

In addition to the well-known operative use of LUS in positioning CVCs and tracheostomy procedures, LUS is an integrative diagnostic tool with CXR for monitoring thrombosis or pneumothorax complications related to CVCs and nasogastric tube displace-
ments (Figure 16) [58-60] cheostomy procedures, LUS is an integrative diagnostic tool with CXR for monitoring ments (Figure [16\)](#page-15-1) [\[58](#page-18-17)[–60\]](#page-18-18).

Figure 16. CVC thrombosis. Right supraclavicular ultrasound exploration highlights the presence **Figure 16.** CVC thrombosis. Right supraclavicular ultrasound exploration highlights the presence of an isocogenic, non-compressible area attributable to thrombosis in the lumen of the subclavian of an isocogenic, non-compressible area attributable to thrombosis in the lumen of the subclavian vein (arrow); it also allows visualization of the course of the catheter, visible as a hyperechoic tubular structure (arrowheads).

5. Conclusions

LUS is a well-established diagnostic tool inextricably linked to the clinical environment and frequently used in ICUs. Despite their reduced diagnostic sensitivity in the anteroposterior supine projection, CXRs nevertheless remain an indispensable 'open window' to the chest that also provide information on parenchymal changes far from the pleura as well as on the cardio-mediastinum.

From a purely radiological point of view, in addition to a well-codified organization, the use of point-of-care LUS as an advanced method in ICU CXR reports can be an essential tool for diagnosing and monitoring areas of decreased transparency around the chest found on CXRs, such as atelectasis, pneumonia, pleural effusion, pulmonary edema, ARDS, and pulmonary contusions, as well as in diagnosing and monitoring pneumothorax and also when checking the positioning of the devices or the complications associated with them.

Author Contributions: Conceptualization, M.D.S., G.D.O. and M.C.; methodology, M.D.S., G.D.O., M.C. and D.V.; validation, L.R.; resources, M.D.S., G.D.O., M.C., D.V. and F.I.; data curation, M.D.S., G.D.O., M.C., C.C., R.R., V.S., L.B. and G.O.; writing—original draft preparation, M.D.S., G.D.O., M.C. and D.V.; writing—review and editing, M.D.S., G.D.O., M.C., C.C. and F.I.; supervision, L.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical review and approval were waived due to the nature of the manuscript.

Informed Consent Statement: Patient consent was waived due to the nature of the manuscript.

Data Availability Statement: Not applicable.

Acknowledgments: In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments). Thanks to Nazareno Capasso for data collection.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Expert Panel on Thoracic Imaging; Laroia, A.T.; Donnelly, E.F.; Henry, T.S.; Berry, M.F.; Boiselle, P.M.; Colletti, P.M.; Kuzniewski, C.T.; Maldonado, F.; Olsen, K.M.; et al. ACR Appropriateness Criteria® Intensive Care Unit Patients. *J. Am. Coll. Radiol.* **2021**, *18*, S62–S72. [\[CrossRef\]](https://doi.org/10.1016/j.jacr.2021.01.017) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/33958119)
- 2. Swensen, S.J.; Peters, S.G.; LeROY, A.J.; Gay, P.C.; Sykes, M.W.; Trastek, V.F. Radiology in the Intensive-Care Unit. *Mayo Clin. Proc.* **1991**, *66*, 396–410. [\[CrossRef\]](https://doi.org/10.1016/S0025-6196(12)60665-X)
- 3. Fabre, C.; Proisy, M.; Chapuis, C.; Jouneau, S.; Lentz, P.-A.; Meunier, C.; Mahé, G.; Lederlin, M. Radiology residents' skill level in chest x-ray reading. *Diagn. Interv. Imaging* **2018**, *99*, 361–370. [\[CrossRef\]](https://doi.org/10.1016/j.diii.2018.04.007)
- 4. Trotman-Dickenson, B. Radiology in the Intensive Care Unit (Part I). *J. Intensiv. Care Med.* **2003**, *18*, 198–210. [\[CrossRef\]](https://doi.org/10.1177/0885066603251897)
- 5. Di Serafino, M.; Notaro, M.; Rea, G.; Iacobellis, F.; Paoli, V.D.; Acampora, C.; Ianniello, S.; Brunese, L.; Romano, L.; Vallone, G. The lung ultrasound: Facts or artifacts? In the era of COVID-19 outbreak. *La Radiol. medica* **2020**, *125*, 738–753. [\[CrossRef\]](https://doi.org/10.1007/s11547-020-01236-5) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/32535787)
- 6. Quarato, C.M.I.; Mirijello, A.; Lacedonia, D.; Russo, R.; Maggi, M.M.; Rea, G.; Simeone, A.; Borelli, C.; Feragalli, B.; Scioscia, G.; et al. Low Sensitivity of Admission Lung US Compared to Chest CT for Diagnosis of Lung Involvement in a Cohort of 82 Patients with COVID-19 Pneumonia. *Medicina* **2021**, *57*, 236. [\[CrossRef\]](https://doi.org/10.3390/medicina57030236)
- 7. Trotman-Dickenson, B. Radiology in the Intensive Care Unit (Part 2). *J. Intensiv. Care Med.* **2003**, *18*, 239–252. [\[CrossRef\]](https://doi.org/10.1177/0885066603254087)
- 8. Al Shahrani, A.; Al-Surimi, K. Daily routine versus on-demand chest radiograph policy and practice in adult ICU patientsclinicians' perspective. *BMC Med. Imaging* **2018**, *18*, 4. [\[CrossRef\]](https://doi.org/10.1186/s12880-018-0248-6)
- 9. Keveson, B.; Clouser, R.D.; Hamlin, M.P.; Stevens, P.; Stinnett-Donnelly, J.M.; Allen, G.B. Adding value to daily chest X-rays in the ICU through education, restricted daily orders and indication-based prompting. *BMJ Open Qual.* **2017**, *6*, e000072. [\[CrossRef\]](https://doi.org/10.1136/bmjoq-2017-000072) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/29435503)
- 10. Ganapathy, A.; Adhikari, N.K.; Spiegelman, J.; Scales, D.C. Routine chest x-rays in intensive care units: A systematic review and meta-analysis. *Crit. Care* **2012**, *16*, R68. [\[CrossRef\]](https://doi.org/10.1186/cc11321)
- 11. Deshpande, R.; Akhtar, S.; Haddadin, A.S. Utility of ultrasound in the ICU. *Curr. Opin. Anaesthesiol.* **2014**, *27*, 123–132. [\[CrossRef\]](https://doi.org/10.1097/ACO.0000000000000057)
- 12. Gil-Rodríguez, J.; de Rojas, J.P.; Aranda-Laserna, P.; Benavente-Fernández, A.; Martos-Ruiz, M.; Peregrina-Rivas, J.-A.; Guirao-Arrabal, E. Ultrasound findings of lung ultrasonography in COVID-19: A systematic review. *Eur. J. Radiol.* **2022**, *148*, 110156. [\[CrossRef\]](https://doi.org/10.1016/j.ejrad.2022.110156)
- 13. Smit, J.M.; Haaksma, M.E.; Winkler, M.H.; Heldeweg, M.L.A.; Arts, L.; Lust, E.J.; Elbers, P.W.G.; Meijboom, L.J.; Girbes, A.R.J.; Heunks, L.M.A.; et al. Lung ultrasound in a tertiary intensive care unit population: A diagnostic accuracy study. *Crit. Care* **2021**, *25*, 339. [\[CrossRef\]](https://doi.org/10.1186/s13054-021-03759-3)
- 14. Lichtenstein, D.A. BLUE-Protocol and FALLS-Protocol: Two applications of lung ultrasound in the critically ill. *Chest* **2015**, *147*, 1659–1670. [\[CrossRef\]](https://doi.org/10.1378/chest.14-1313) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/26033127)
- 15. Bekgoz, B.; Kilicaslan, I.; Bildik, F.; Keles, A.; Demircan, A.; Hakoglu, O.; Coskun, G.; Demir, H.A. BLUE protocol ultrasonography in Emergency Department patients presenting with acute dyspnea. *Am. J. Emerg. Med.* **2019**, *37*, 2020–2027. [\[CrossRef\]](https://doi.org/10.1016/j.ajem.2019.02.028)
- 16. Rea, G.; Sperandeo, M.; Di Serafino, M.; Vallone, G.; Tomà, P. Neonatal and pediatric thoracic ultrasonography. *J. Ultrasound* **2019**, *22*, 121–130. [\[CrossRef\]](https://doi.org/10.1007/s40477-019-00357-6) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/30778892)
- 17. Sperandeo, M.; Rea, G.; Filabozzi, P.; Carnevale, V. Lung Ultrasound and Chest X-Rays: Together to Improve the Diagnosis. *Respiration* **2017**, *93*, 226–227. [\[CrossRef\]](https://doi.org/10.1159/000455138)
- 18. Di Serafino, M.; Vallone, G. The role of point of care ultrasound in radiology department: Update and prospective. A statement of Italian college ultrasound. *La Radiol. Medica* **2020**, *126*, 636–641. [\[CrossRef\]](https://doi.org/10.1007/s11547-020-01301-z) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/33146845)
- 19. Das Villgran, V.; Lyons, C.; Nasrullah, A.; Abalos, C.C.; Bihler, E.D.; Alhajhusain, A. Acute Respiratory Failure. *Crit. Care Nurs. Q.* **2022**, *45*, 233–247. [\[CrossRef\]](https://doi.org/10.1097/CNQ.0000000000000408)
- 20. Lichtenstein, D. Lung ultrasound in the critically ill. *Curr. Opin. Crit. Care* **2014**, *20*, 315–322. [\[CrossRef\]](https://doi.org/10.1097/MCC.0000000000000096) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/24758984)
- 21. Haaksma, M.E.; Smit, J.M.; Heldeweg, M.L.A.; Nooitgedacht, J.S.B.; de Grooth, H.J.; Jonkman, A.H.M.; Girbes, A.R.J.; Heunks, L.; Tuinman, P.R. Extended Lung Ultrasound to Differentiate Between Pneumonia and Atelectasis in Critically Ill Patients: A Diagnostic Accuracy Study. *Crit. Care Med.* **2021**, *50*, 750–759. [\[CrossRef\]](https://doi.org/10.1097/CCM.0000000000005303) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/34582414)
- 22. Dicker, S.A. Lung Ultrasound for Pulmonary Contusions. *Vet. Clin. North Am. Small Anim. Pract.* **2021**, *51*, 1141–1151. [\[CrossRef\]](https://doi.org/10.1016/j.cvsm.2021.07.001) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/34521570)
- 23. Assaad, S.; Kratzert, W.B.; Shelley, B.; Friedman, M.B.; Perrino, A. Assessment of Pulmonary Edema: Principles and Practice. *J. Cardiothorac. Vasc. Anesthesia* **2018**, *32*, 901–914. [\[CrossRef\]](https://doi.org/10.1053/j.jvca.2017.08.028) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/29174750)
- 24. Wang, Y.; Shen, Z.; Lu, X.; Zhen, Y.; Li, H. Sensitivity and specificity of ultrasound for the diagnosis of acute pulmonary edema: A systematic review and meta-analysis. *Med. Ultrason.* **2018**, *1*, 32–36. [\[CrossRef\]](https://doi.org/10.11152/mu-1223)
- 25. Shao, R.-J.; Du, M.-J.; Xie, J.-T. Use of lung ultrasound for the diagnosis and treatment of pleural effusion. *Eur. Rev. Med. Pharmacol. Sci.* **2022**, *26*, 8771–8776. [\[CrossRef\]](https://doi.org/10.26355/eurrev_202212_30548)
- 26. Brogi, E.; Gargani, L.; Bignami, E.; Barbariol, F.; Marra, A.; Forfori, F.; Vetrugno, L. Thoracic ultrasound for pleural effusion in the intensive care unit: A narrative review from diagnosis to treatment. *Crit. Care* **2017**, *21*, 325. [\[CrossRef\]](https://doi.org/10.1186/s13054-017-1897-5)
- 27. Thachuthara-George, J. Pneumothorax in patients with respiratory failure in ICU. *J. Thorac. Dis.* **2021**, *13*, 5195–5204. [\[CrossRef\]](https://doi.org/10.21037/jtd-19-3752)
- 28. Kitazono, M.T.; Lau, C.T.; Parada, A.N.; Renjen, P.; Miller, W.T. Differentiation of Pleural Effusions From Parenchymal Opacities: Accuracy of Bedside Chest Radiography. *Am. J. Roentgenol.* **2010**, *194*, 407–412. [\[CrossRef\]](https://doi.org/10.2214/AJR.09.2950)
- 29. Wongwaisayawan, S.; Suwannanon, R.; Sawatmongkorngul, S.; Kaewlai, R. Emergency Thoracic US: The Essentials. *Radiographics* **2016**, *36*, 640–659. [\[CrossRef\]](https://doi.org/10.1148/rg.2016150064)
- 30. Breitkopf, R.; Treml, B.; Rajsic, S. Lung Sonography in Critical Care Medicine. *Diagnostics* **2022**, *12*, 1405. [\[CrossRef\]](https://doi.org/10.3390/diagnostics12061405)
- 31. Mojoli, F.; Bouhemad, B.; Mongodi, S.; Lichtenstein, D. Lung Ultrasound for Critically Ill Patients. *Am. J. Respir. Crit. Care Med.* **2019**, *199*, 701–714, Erratum in: *Am. J. Respir. Crit. Care Med.* **2020**, *201*, 1015; Erratum in: *Am. J. Respir. Crit. Care Med.* **2020**, *201*, 1454. [\[CrossRef\]](https://doi.org/10.1164/rccm.201802-0236CI)
- 32. Mayo, P.H.; Copetti, R.; Feller-Kopman, D.; Mathis, G.; Maury, E.; Mongodi, S.; Mojoli, F.; Volpicelli, G.; Zanobetti, M. Thoracic ultrasonography: A narrative review. *Intensiv. Care Med.* **2019**, *45*, 1200–1211. [\[CrossRef\]](https://doi.org/10.1007/s00134-019-05725-8)
- 33. Sidhu, P.S.; Cantisani, V.; Dietrich, C.F.; Gilja, O.H.; Saftoiu, A.; Bartels, E.; Bertolotto, M.; Calliada, F.; Clevert, D.-A.; Cosgrove, D.; et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). *Ultraschall der Med. Eur. J. Ultrasound* **2018**, *39*, e2–e44. [\[CrossRef\]](https://doi.org/10.1055/a-0586-1107)
- 34. Quarato, C.M.I.; Sperandeo, M. Letter to the Editor Regarding the Article: "Vascularization of Primary, Peripheral Lung Carcinoma in CEUS—A Retrospective Study (n = 89 Patients)" by Findeisen H et al. *Ultraschall der Med. Eur. J. Ultrasound* **2020**, *42*, 321–322. [\[CrossRef\]](https://doi.org/10.1055/a-1088-3432) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/32040970)
- 35. Quarato, C.M.; Cipriani, C.; Dimitri, L.; Lacedonia, D.; Graziano, P.; Copetti, M.; De Cosmo, S.; Simeone, A.; Scioscia, G.; Barbaro, M.F.; et al. Assessing value of contrast-enhanced ultrasound vs. conventional transthoracic ultrasound in improving diagnostic yield of percutaneous needle biopsy of peripheral lung lesions. *Eur. Rev. Med. Pharmacol. Sci.* **2021**, *25*, 5781–5789. [\[CrossRef\]](https://doi.org/10.26355/eurrev_202109_26796)
- 36. Quarato, C.M.I.; Feragalli, B.; Lacedonia, D.; Rea, G.; Scioscia, G.; Maiello, E.; Di Micco, C.; Borelli, C.; Mirijello, A.; Graziano, P.; et al. Contrast-Enhanced Ultrasound in Distinguishing between Malignant and Benign Peripheral Pulmonary Consolidations: The Debated Utility of the Contrast Enhancement Arrival Time. *Diagnostics* **2023**, *13*, 666. [\[CrossRef\]](https://doi.org/10.3390/diagnostics13040666)
- 37. Toy, D.; Siegel, M.D.; Rubinowitz, A.N. Imaging in the Intensive Care Unit. *Semin. Respir. Crit. Care Med.* **2022**, *43*, 899–923. [\[CrossRef\]](https://doi.org/10.1055/s-0042-1750041) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/36442475)
- 38. Adler, A.C.; von Ungern-Sternberg, B.S.; Matava, C.T. Lung ultrasound and atelectasis—The devil is in the details. *Pediatr. Anesthesia* **2021**, *31*, 1269–1270. [\[CrossRef\]](https://doi.org/10.1111/pan.14286)
- 39. Peroni, D.; Boner, A. Atelectasis: Mechanisms, diagnosis and management. *Paediatr. Respir. Rev.* **2000**, *1*, 274–278. [\[CrossRef\]](https://doi.org/10.1053/prrv.2000.0059) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/12531090)
- 40. Duggan, M.; Kavanagh, B.P.; Warltier, D.C. Pulmonary Atelectasis: A pathogenic perioperative entity. *Anesthesiology* **2005**, *102*, 838–854. [\[CrossRef\]](https://doi.org/10.1097/00000542-200504000-00021)
- 41. Maffessanti, M.; Berlot, G.; Bortolotto, P. Chest roentgenology in the intensive care unit: An overview. *Eur. Radiol.* **1998**, *8*, 69–78. [\[CrossRef\]](https://doi.org/10.1007/s003300050342)
- 42. Rubinowitz, A.N.; Siegel, M.D.; Tocino, I. Thoracic Imaging in the ICU. *Crit. Care Clin.* **2007**, *23*, 539–573. [\[CrossRef\]](https://doi.org/10.1016/j.ccc.2007.06.001)
- 43. Lichtenstein, D.; Mezière, G.; Seitz, J. The The dynamic air bronchogram. A lung ultrasound sign of alveolar consolidation ruling out atelectasis. *Chest* **2009**, *135*, 1421–1425. [\[CrossRef\]](https://doi.org/10.1378/chest.08-2281)
- 44. Lichtenstein, D.A.; Lascols, N.; Prin, S.; Mezière, G. The "lung pulse": An early ultrasound sign of complete atelectasis. *Intensiv. Care Med.* **2003**, *29*, 2187–2192. [\[CrossRef\]](https://doi.org/10.1007/s00134-003-1930-9)
- 45. Lanks, C.W.; Musani, A.I.; Hsia, D.W. Community-acquired Pneumonia and Hospital-acquired Pneumonia. *Med. Clin. N. Am.* **2019**, *103*, 487–501. [\[CrossRef\]](https://doi.org/10.1016/j.mcna.2018.12.008) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/30955516)
- 46. Woodhead, M.; Welch, C.A.; Harrison, D.A.; Bellingan, G.; Ayres, J.G. Community-acquired pneumonia on the intensive care unit: Secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. *Crit. Care* **2006**, *10* (Suppl. S2), S1. [\[CrossRef\]](https://doi.org/10.1186/cc4927) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/16934135)
- 47. Papazian, L.; Klompas, M.; Luyt, C.-E. Ventilator-associated pneumonia in adults: A narrative review. *Intensiv. Care Med.* **2020**, *46*, 888–906. [\[CrossRef\]](https://doi.org/10.1007/s00134-020-05980-0)
- 48. Walker, S.P.; Morley, A.J.; Stadon, L.; De Fonseka, D.; Arnold, D.T.; Medford, A.R.; Maskell, N.A. Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients. *Chest* **2017**, *151*, 1099–1105. [\[CrossRef\]](https://doi.org/10.1016/j.chest.2016.12.014) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/28025056)
- 49. Saguil, A.; Wyrick, K.; Hallgren, J. Diagnostic approach to pleural effusion. *Am. Fam. Physician.* **2014**, *90*, 99–104.
- 50. Aboudara, M.; Maldonado, F. Update in the Management of Pleural Effusions. *Med. Clin. N. Am.* **2019**, *103*, 475–485. [\[CrossRef\]](https://doi.org/10.1016/j.mcna.2018.12.007)
- 51. Alwi, I. Diagnosis and management of cardiogenic pulmonary edema. *Acta Med. Indones.* **2010**, *42*, 176–184.
- 52. Aissaoui, N.; Hamzaoui, O.; Price, S. Ten questions ICU specialists should address when managing cardiogenic acute pulmonary oedema. *Intensiv. Care Med.* **2022**, *48*, 482–485. [\[CrossRef\]](https://doi.org/10.1007/s00134-022-06639-8) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/35178595)
- 53. Meyer, N.J.; Gattinoni, L.; Calfee, C.S. Acute respiratory distress syndrome. *Lancet* **2021**, *398*, 622–637. [\[CrossRef\]](https://doi.org/10.1016/S0140-6736(21)00439-6) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/34217425)
- 54. Fan, E.; Brodie, D.; Slutsky, A.S. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. *JAMA* **2018**, *319*, 698–710. [\[CrossRef\]](https://doi.org/10.1001/jama.2017.21907)
- 55. Rendeki, S.; Molnár, T.F. Pulmonary contusion. *J. Thorac. Dis.* **2019**, *11* (Suppl. S2), S141–S151. [\[CrossRef\]](https://doi.org/10.21037/jtd.2018.11.53)
- 56. Shah, K.; Tran, J.; Schmidt, L. Traumatic pneumothorax: Updates in diagnosis and management in the emergency department. *Emerg. Med. Pract.* **2022**, *25* (Suppl. S1), 1–28.
- 57. Alsohime, F.; Temsah, M.-H.; Al-Eyadhy, A.; Ghulman, S.; Mosleh, H.; Alsohime, O. Technical Aspects of Intensive Care Unit Management: A Single-Center Experience at a Tertiary Academic Hospital. *J. Multidiscip. Health.* **2021**, *14*, 869–875. [\[CrossRef\]](https://doi.org/10.2147/JMDH.S294905)
- 58. Plata, P.; Gaszyński, T. Ultrasound-guided percutaneous tracheostomy. Anaesthesiol. Intensiv. Ther. 2019, 51, 126-132. [\[CrossRef\]](https://doi.org/10.5114/ait.2019.86277) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/31268274)
- 59. Saugel, B.; Scheeren, T.W.L.; Teboul, J.-L. Ultrasound-guided central venous catheter placement: A structured review and recommendations for clinical practice. *Crit. Care* **2017**, *21*, 225. [\[CrossRef\]](https://doi.org/10.1186/s13054-017-1814-y)
- 60. Tsujimoto, H.; Tsujimoto, Y.; Nakata, Y.; Akazawa, M.; Kataoka, Y. Ultrasonography for confirmation of gastric tube placement. *Cochrane Database Syst. Rev.* **2017**, *2017*, CD012083. [\[CrossRef\]](https://doi.org/10.1002/14651858.CD012083.pub2)

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.